

Investigator-Initiated Study: ABI-007 Strives to Reach Enrollment Targets for Interim Analysis

ABI-007, the neoadjuvant trial of Trastuzumab in combination with dose-dense ABI007 (Abraxane) followed by Vinorelbine sponsored by Georgia CORE and funded by Abraxis, is actively accruing patients.

Currently, the study has 26% patient accrual towards the projected goal and 50% towards the interim analysis. The study is open at the following Georgia CORE research network sites:

- Dekalb Medical/Georgia Cancer Specialists Emory/Winship Cancer Institute
- Georgia Cancer Center for Excellence/Grady Health System
- Northeast Georgia Cancer Care
- Piedmont Hospital/Peachtree Hematology Oncology Consultants.

Memorial Health Receives High Marks during GOG Audit

Georgia CORE is pleased to announce that the Curtis and Elizabeth Anderson Cancer Institute at Memorial Health University received great scores during the Gynecologic Oncology Group (GOG) audit.

We are pleased to congratulate Memorial Health on their exemplary marks.

For study information contact:

Diane Hicklin-Coleman, MPA
Research Director
770-313-4055
404-588-4082
dhicklin@georgiacore.org

Pfizer Study A7471028 Treatment of Advanced NSC Lung Cancer Enrolls First Patient

The first patient (at a Research Network site) was enrolled in the Pfizer study A7471028, 'Randomized Phase II Trial of PF-00299804 versus Erlotinib for the treatment of advanced non-small cell lung cancer after failure of at least one prior chemotherapy regimen' at the John B. Amos Cancer Center in Columbus, GA. The study is also open in the following CORE Research Network sites:

- Dekalb Medical/Georgia Cancer Specialists
- Emory Winship Cancer Institute
- Northeast Georgia Health System
- Phoebe Putnev Memorial Hospital.

Georgia Investigator's Access Georgia Breast Cancer Trial Webcast

The latest webcast update for Georgia Investigators on the Investigator-Initiated breast cancer studies being conducted through the Georgia CORE Research Network is available at:

<http://www.georgiacore.org/articleDetail.aspx?articleID=104>.

In the webcast, Dr. Ruth O'Regan provides updates on the following studies:

- Randomized Phase II Trial of Sequential Docetaxel followed by Capecitabine versus Concomitant Docetaxel/Capecitabine as Induction Therapy for Early Stage Breast Cancer
- Phase II Neoadjuvant Trial of Trastuzumab in Combination with Dose-Dense ABI-007 (Abraxane) Followed by Vinorelbine for HER2 Overexpressing Early Stage Breast Cancer
- Phase II Trial of Gemcitabine and Oxaliplatin for ER-, PR-, HER2Neu- (Triple Negative) Metastatic Breast Cancer
- Phase II Trial of Pre-operative Docetaxel-Cytosin (TC) in Patients with Hormone Receptor-Positive Cancers with Recurrence Scores greater than or equal to 25
- Randomized Phase II Trial of Pre-operative Docetaxel-Cytosin (TC) and Exemestane in Patients with Hormone Receptor-Positive Cancers with Recurrence Scores less than 25.

Event Calendar:

7/24-7/29/2009-
Best of ASCO®
Hyatt Regency Atlanta
www.asco.org

7/24-26/2009-
GASCO Annual Meeting
Hyatt Regency Atlanta
www.gasco.us

7/26-7/30/2009-
Emory Winship Cancer Institute Presents "Updates in Hematology and Medical Oncology"
The Sanctuary, Kiawah Island, SC
www.med.emory.edu/CME

Georgia CORE®
50 Hurt Plaza
Suite 704
Atlanta, GA 30303
404-523-8735
www.georgiacore.org
info@georgiacore.org

Georgia CORE is generously supported by the Georgia Cancer Coalition, Emory Winship Cancer Institute, an NCI-designated cancer center, and Georgia oncologists.